genetics
Helmah Kargar; Maryam Peymani
Volume 29, Issue 3 , September and October 2022, , Pages 318-329
Abstract
Background: Changes in the SET1B gene expression, can directly affect the incidence and progression of cancer. The gene encoding lncRNA LIMT is transcribed as antisense in the opposite direction to SET1B. The aim of this study was to investigate the expression of lncRNA LIMT and SETD1B in ...
Read More
Background: Changes in the SET1B gene expression, can directly affect the incidence and progression of cancer. The gene encoding lncRNA LIMT is transcribed as antisense in the opposite direction to SET1B. The aim of this study was to investigate the expression of lncRNA LIMT and SETD1B in tumor tissues compared to adjacent normal in colorectal cancer and the relation between these two genes is related to the clinical features of tumor tissues.
Materials and methods: After collecting 40 tumor and adjacent normal tissues, Total RNA extraction and cDNA synthesis were performed. Then the expression levels of the desired genes in tumor and normal tissues was compared. Finally, the obtained results were statistically analyzed by Prism software.
Results: The expression level of SETD1B increased 1.8 fold changes in tumor samples (p = 0.01103) while the expression level of lncRNA LIMT in tumor tissue did not change significantly compared to normal tissue (p = 0.5391). In addition, the expression levels of SET1B and lncRNA LIMT in the two age groups over 60 years and under 60 years in tumor tissues did not change significantly. ROC analysis also showed that SETD1B with AUC = 0.336 and CI = 0.8771 - 0.9902 can separate the patient population from the healthy and can help diagnose colorectal cancer.
Conclusion: According to the results of this study, it can be said that SETD1B is increased in tumor tissue and can be used as a biomarker for colorectal cancer.